title: Predictors and prognosis of status epilepticus treated with intravenous sodium valproate.
abstract: OBJECTIVE
  To retrospectively review the efficacy of intravenous sodium valproate (VPAiv) treatment of status epilepticus (SE) and analyse predictive factors for seizure control and death.
  
  
  METHODS
  Patients were included with a diagnosis of SE who had received intravenous sodium valproate (VPAiv) during 2005-2007 at Srinagarind Hospital, Khon Kaen University, Thailand. Logistic regression analysis with a stepwise approach was used to evaluate the predictors of seizure control and death.
  
  
  RESULTS
  Thirty-two cases were diagnosed as SE with VPAiv treatment; 12 and 20 patients received VPAiv as the first- and second-line therapy, respectively. SE ceased in nine out of 12 patients (75%) and in seven out of 20 (35%) patients with VPAiv as the first- and second-line therapy, respectively. No serious cardiovascular compromise was recorded. The first-line therapy of VPAiv was the only factor that was significantly related to seizure control with an adjusted odds ratio [OR] of 5.571; 95% confidence interval [CI] of 1.128-27.523. Initial leukocytosis and hypotension were significantly associated with death (adjusted OR: 22.765, 95% CI: 1.176-440.640 and adjusted OR: 37.591, 95% CI: 3.035-465.571, respectively).
  
  
  CONCLUSIONS
  For SE patients who received VPAiv treatment, the first-line VPAiv was effective. Initial leukocytosis and hypotension were factors that correlated with death.
authors.affiliation: Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. somtia@kku.ac.th
authors.forename: Somsak
authors.initials: S
authors.lastname: Tiamkao
authors.forename: Kittisak
authors.initials: K
authors.lastname: Sawanyawisuth
mesh_terms: D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D003627:Data Interpretation, Statistical; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D016015:Logistic Models; D008297:Male; D016017:Odds Ratio; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D012640:Seizures / Q000517:prevention & control; D013226:Status Epilepticus / Q000188:drug therapy*; D016019:Survival Analysis; D016896:Treatment Outcome; D014635:Valproic Acid / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D000927:Anticonvulsants; D014635:Valproic Acid